



Complete Summary

TITLE

Non-selective non-steroidal anti-inflammatory drugs (NSAIDs): percentage of patients treated with a non-selective NSAID who have risk factors for GI bleeding and who are treated concomitantly with either misoprostol or a proton pump inhibitor (PPI).

SOURCE(S)

MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. *Arthritis Rheum* 2004 Apr 15;51(2):193-202. [PubMed](#)

Saag KG, Olivieri JJ, Patino F, Mikuls TR, Allison JJ, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. *Arthritis Rheum* 2004 Jun 15;51(3):337-49. [89 references] [PubMed](#)

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients treated with a non-selective non-steroidal anti-inflammatory drug (NSAID) who have risk factors for gastrointestinal (GI) bleeding and who are treated concomitantly with either misoprostol or a proton pump inhibitor (PPI).

RATIONALE

Gastrointestinal (GI) prophylaxis can reduce the risk of GI bleeding in users of non-selective non-steroidal anti-inflammatory drugs (NSAIDs).

The efficacy of proton pump inhibitors, misoprostol (a long-acting prostaglandin E₁ agonist), and H₂-blockers for the prevention of NSAID-induced gastroduodenal ulceration has been assessed via meta-analyses and subsequent randomized controlled trials (RCTs).

The American Academy of Orthopaedic Surgeons' clinical guidelines on osteoarthritis of the knee and the American College of Rheumatology suggest that when considering analgesics/NSAIDs, patients should be assessed for risk factors for GI or renal toxicity and if risk factors are present, a gastroprotective agent or cyclooxygenase 2 (COX-2) inhibitor should be considered.

PRIMARY CLINICAL COMPONENT

Non-selective non-steroidal anti-inflammatory drugs (NSAIDs); gastrointestinal (GI) bleeding risk factors; gastrointestinal prophylaxis; misoprostol; proton pump inhibitor (PPI)

DENOMINATOR DESCRIPTION

Patients treated with a non-selective non-steroidal anti-inflammatory drug (NSAID) who have risk factors for gastrointestinal (GI) bleeding*

***Note:** For the purpose of this measure, heightened risk for GI bleeding is defined as age greater than or equal to 75 years, history of peptic ulcer disease, history of GI bleeding, or glucocorticoid use.

NUMERATOR DESCRIPTION

Patients who are treated concomitantly with either misoprostol or a proton pump inhibitor (PPI)

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence
- A formal consensus procedure involving experts in relevant clinical, methodological, and organizational sciences
- A systematic review of the clinical literature
- One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Ambulatory Care
Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Advanced Practice Nurses
Physician Assistants
Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Individual Clinicians

TARGET POPULATION AGE

Unspecified

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Gastrointestinal (GI) risks of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). A number of meta-analyses have evaluated the relationship between the use of aspirin (greater than 325 mg/day) and other nonaspirin, nonselective NSAIDs and the risk for clinically defined adverse GI events. Exposure to NSAIDs has been associated with a 2.7 to 5.4-fold increased risk of various GI adverse events in these various studies.

EVIDENCE FOR BURDEN OF ILLNESS

Saag KG, Olivieri JJ, Patino F, Mikuls TR, Allison JJ, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. *Arthritis Rheum* 2004 Jun 15;51(3):337-49. [89 references] [PubMed](#)

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness
Safety

Data Collection for the Measure

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

Patients treated with a non-selective non-steroidal anti-inflammatory drug (NSAID) who have risk factors for gastrointestinal (GI) bleeding

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

Patients treated with a non-selective non-steroidal anti-inflammatory drug (NSAID) who have risk factors for gastrointestinal (GI) bleeding*

***Note:** For the purpose of this measure, heightened risk for GI bleeding is defined as age greater than or equal to 75 years, history of peptic ulcer disease, history of GI bleeding, or glucocorticoid use.

Exclusions

Unspecified

RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

DENOMINATOR (INDEX) EVENT

Therapeutic Intervention

DENOMINATOR TIME WINDOW

Unspecified

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Patients who are treated concomitantly with either misoprostol or a proton pump inhibitor (PPI)

Exclusions

Unspecified

MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

NUMERATOR TIME WINDOW

Episode of care

DATA SOURCE

Administrative data
Medical record
Pharmacy data

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

A multidisciplinary expert panel comprised of nationally recognized experts discussed and rated the validity of each of the proposed measures based on the evidence and their expert opinion using a modification of the RAND/UCLA Appropriateness Method.

EVIDENCE FOR RELIABILITY/VALIDITY TESTING

MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. *Arthritis Rheum* 2004 Apr 15;51(2):193-202. [PubMed](#)

Saag KG, Olivieri JJ, Patino F, Mikuls TR, Allison JJ, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. *Arthritis Rheum* 2004 Jun 15;51(3):337-49. [89 references] [PubMed](#)

Identifying Information

ORIGINAL TITLE

Quality indicator 4. Non-selective NSAID use: GI prophylaxis.

MEASURE COLLECTION

[The Arthritis Foundation's Quality Indicator Project](#)

MEASURE SET NAME

[The Arthritis Foundation's Quality Indicator Set for Analgesics](#)

SUBMITTER

Arthritis Foundation

DEVELOPER

Arthritis Foundation
RAND Health
University of Alabama at Birmingham

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2004 Jun

MEASURE STATUS

This is the current release of the measure.

SOURCE(S)

MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum 2004 Apr 15;51(2):193-202. [PubMed](#)

Saag KG, Olivieri JJ, Patino F, Mikuls TR, Allison JJ, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. Arthritis Rheum 2004 Jun 15;51(3):337-49. [89 references] [PubMed](#)

MEASURE AVAILABILITY

The individual measure, "Quality Indicator 4. Non-selective NSAID Use: GI Prophylaxis," is published in "Measuring Quality in Arthritis Care: The Arthritis Foundation's Quality Indicator Set for Analgesics."

For more information contact:
Arthritis Foundation

P.O. Box 7669
Atlanta, GA 30357-0669
Telephone: 404-872-7100 or 1-800-568-4045
Web site: www.arthritis.org

OR

RAND Health
1776 Main Street
P.O. Box 2138
Santa Monica, CA 90407-2138
Telephone: (310) 393-0411, ext. 7775
Web site: www.rand.org/health
E-mail: RAND_Health@rand.org

NQMC STATUS

This NQMC summary was completed by ECRI on August 7, 2007. The information was verified by the measure developer on September 10, 2007.

COPYRIGHT STATEMENT

No copyright restrictions apply.

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at <http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008

